MINIMED GROUP INC (MMED) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 8, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q1 FY2027, filed Sep 8, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MMED SEC filings page.
MINIMED GROUP INC (MMED) reported $3.1B in revenue for fiscal year 2026, up 14.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue expansion is being overwhelmed by margin compression and a shift from operating cash generation to cash consumption.
Revenue reached$3.10B in FY2026, yet gross margin narrowed to54.2% . Paired with a$190M operating loss, that combination says added volume is not currently translating into better cost absorption.
Gross margin fell from
FY2026 operating cash flow was
Financial Health Signals
Scored against operating companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of MINIMED GROUP INC's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
MINIMED GROUP INC has an operating margin of -6.1%, meaning the company loses $6 on every $100 of revenue. This results in a profitability score of 37/100. This is down from -5.4% the prior year.
MINIMED GROUP INC's revenue grew 14.3% year-over-year to $3.1B, a solid pace of expansion. This earns a growth score of 70/100.
MINIMED GROUP INC carries a low D/E ratio of 0.28, meaning only $0.28 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 70/100, indicating a strong balance sheet with room for future borrowing.
MINIMED GROUP INC's current ratio of 1.92 indicates adequate short-term liquidity, earning a score of 57/100. The company can meet its near-term obligations, though with limited headroom.
MINIMED GROUP INC's operations used $197.0M of cash, and capex of $223.0M added to the outflow, for a free cash flow shortfall of $420.0M. This results in a cash flow score of 13/100.
MINIMED GROUP INC posts a -9.2% return on equity (ROE), meaning it loses $9 for every $100 of shareholders' equity. This results in a returns score of 46/100. This is down from -6.4% the prior year.
MINIMED GROUP INC scores 4.53, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($6.6B) relative to total liabilities ($1.0B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
MINIMED GROUP INC passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 1 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
MINIMED GROUP INC reported a net loss of $333.0M while operations used $197.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
MINIMED GROUP INC generated $843.0M in revenue in Q1 2027. This represents an increase of 16.6% from the same quarter a year earlier.
MINIMED GROUP INC's EBITDA was $46.0M in Q1 2027, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 76.9% from the same quarter a year earlier.
MINIMED GROUP INC reported $0 in net income in Q1 2027. This represents an increase of 100.0% from the same quarter a year earlier.
MINIMED GROUP INC earned $0.00 per diluted share (EPS) in Q1 2027. This represents an increase of 100.0% from the same quarter a year earlier. Against the prior quarter it is up 100.0%.
Cash & Balance Sheet
MINIMED GROUP INC recorded an outflow of $90.0M in free cash flow in Q1 2027, representing a cash shortfall after capex. This represents an increase of 53.6% from the same quarter a year earlier. Against the prior quarter it is up 60.2%.
MINIMED GROUP INC held $207.0M in cash as of Q1 2027; long-term debt is not reported for that period.
Not reported for Q1 2027.
Margins & Returns
MINIMED GROUP INC's gross margin was 55.2% in Q1 2027, indicating the percentage of revenue retained after direct costs. This is down 1.4 percentage points from the same quarter a year earlier.
MINIMED GROUP INC's operating margin was 0.6% in Q1 2027, reflecting core business profitability. This is up 2.4 percentage points from the same quarter a year earlier.
MINIMED GROUP INC's net profit margin was 0.0% in Q1 2027, showing the share of revenue converted to profit. This is up 2.6 percentage points from the same quarter a year earlier.
MINIMED GROUP INC's ROE was 0.0% in Q1 2027, measuring profit generated per dollar of shareholder equity. This is up 0.5 percentage points from the same quarter a year earlier.
Capital Allocation
MINIMED GROUP INC invested $115.0M in research and development in Q1 2027. This represents a decrease of 8.0% from the same quarter a year earlier.
MINIMED GROUP INC invested $41.0M in capex in Q1 2027, funding long-term assets and infrastructure. This represents a decrease of 22.6% from the same quarter a year earlier. Against the prior quarter it is down 26.8%.
Not reported for Q1 2027.
MMED Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $843.0M+16.6% | N/A | $790.0M+15.0% | N/A | $723.0M | N/A | $687.0M | N/A |
| Cost of Revenue | $378.0M+20.4% | N/A | $428.0M+46.6% | N/A | $314.0M | N/A | $292.0M | N/A |
| Gross Profit | $465.0M+13.7% | N/A | $362.0M-8.4% | N/A | $409.0M | N/A | $395.0M | N/A |
| R&D Expenses | $115.0M-8.0% | N/A | $114.0M+1.8% | N/A | $125.0M | N/A | $112.0M | N/A |
| SG&A Expenses | $312.0M+10.2% | N/A | $309.0M+15.3% | N/A | $283.0M | N/A | $268.0M | N/A |
| Operating Income | $5.0M+138.5% | N/A | -$100.0M-576.2% | N/A | -$13.0M | N/A | $21.0M | N/A |
| EBITDA | $46.0M+76.9% | N/A | N/A | N/A | $26.0M | N/A | N/A | N/A |
| Income Tax | $4.0M+33.3% | N/A | $12.0M-57.1% | N/A | $3.0M | N/A | $28.0M | N/A |
| Net Income | $0+100.0% | N/A | -$119.0M-1090.0% | -$5.0M0.0% | -$19.0M0.0% | N/A | -$10.0M | -$5.0M |
| EPS (Basic) | $0.00+100.0% | -$0.71-4.4% | -$0.47-1075.0% | N/A | -$0.08 | -$0.68 | -$0.04 | N/A |
| EPS (Diluted) | $0.00+100.0% | -$0.71-4.4% | -$0.47-1075.0% | N/A | -$0.08 | -$0.68 | -$0.04 | N/A |
| Diluted Shares (Avg) | 281M+11.2% | N/A | 253M0.0% | N/A | 253M | N/A | 253M | N/A |
Not reported in any period shown, so not listed: Interest Expense.
MMED Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $4.7B | $4.6B+10.2% | $4.3B | N/A | N/A | $4.2B | N/A | N/A |
| Current Assets | $1.4B | $1.3B+43.6% | $1.1B | N/A | N/A | $939.0M | N/A | N/A |
| Cash & Equivalents | $207.0M+2200.0% | $298.0M+2609.1% | $10.0M0.0% | N/A | $9.0M | $11.0M | $10.0M | N/A |
| Short-Term Investments | $0 | $0 | $0 | N/A | $0 | $0 | $0 | N/A |
| Inventory | $356.0M | $341.0M+9.6% | $408.0M | N/A | N/A | $311.0M | N/A | N/A |
| Accounts Receivable | $180.0M | $200.0M-64.9% | $653.0M | N/A | N/A | $570.0M | N/A | N/A |
| Long-Term Investments | $0 | $0 | $0 | N/A | $0 | $0 | $0 | N/A |
| Goodwill | $2.3B | $2.3B0.0% | $2.3B | N/A | N/A | $2.3B | N/A | N/A |
| Total Liabilities | $1.1B | $1.0B+17.0% | $881.0M | N/A | N/A | $871.0M | N/A | N/A |
| Current Liabilities | $782.0M | $702.0M-1.1% | $696.0M | N/A | N/A | $710.0M | N/A | N/A |
| Non-Current Liabilities | $316.0M | $317.0M+96.9% | $185.0M | N/A | N/A | $161.0M | N/A | N/A |
| Total Equity | $3.6B+2.3% | $3.6B+8.4% | $3.5B-0.7% | $3.6B+2.8% | $3.5B+1.6% | $3.3B | $3.5B | $3.5B |
| Retained Earnings | -$116.0M | -$116.0M | N/A | N/A | N/A | $0 | N/A | N/A |
Not reported in any period shown, so not listed: Long-Term Debt.
MMED Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$49.0M+65.2% | -$170.0M-304.8% | N/A | N/A | -$141.0M | $83.0M | N/A | N/A |
| Depreciation & Amortization | $41.0M+5.1% | $39.0M+2.6% | N/A | N/A | $39.0M | $38.0M | N/A | N/A |
| Stock-Based Compensation | $10.0M+11.1% | N/A | $11.0M0.0% | N/A | $9.0M | N/A | $11.0M | N/A |
| Capital Expenditures | $41.0M-22.6% | $56.0M-1.8% | N/A | N/A | $53.0M | $57.0M | N/A | N/A |
| Free Cash Flow | -$90.0M+53.6% | -$226.0M-969.2% | N/A | N/A | -$194.0M | $26.0M | N/A | N/A |
| Investing Cash Flow | -$41.0M+34.9% | -$56.0M+1.8% | N/A | N/A | -$63.0M | -$57.0M | N/A | N/A |
| Financing Cash Flow | $0-100.0% | $512.0M+2148.0% | N/A | N/A | $202.0M | -$25.0M | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
MMED Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 55.2%-1.4pp | N/A | 45.8%-11.7pp | N/A | 56.6% | N/A | 57.5% | N/A |
| Operating Margin | 0.6%+2.4pp | N/A | -12.7%-15.7pp | N/A | -1.8% | N/A | 3.1% | N/A |
| Net Margin | 0.0%+2.6pp | N/A | -15.1%-13.6pp | N/A | -2.6% | N/A | -1.5% | N/A |
| Return on Equity | 0.0%+0.5pp | N/A | -3.4%-3.1pp | -0.1%0.0pp | -0.5%0.0pp | N/A | -0.3% | -0.1% |
| Return on Assets | 0.0% | N/A | -2.7% | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | 1.81 | 1.92+0.6x | 1.59 | N/A | N/A | 1.32 | N/A | N/A |
| Debt-to-Equity | 0.30 | 0.280.0x | 0.25 | N/A | N/A | 0.26 | N/A | N/A |
| Asset Turnover | 0.18 | N/A | 0.18 | N/A | N/A | N/A | N/A | N/A |
| FCF Margin | -10.7%+16.1pp | N/A | N/A | N/A | -26.8% | N/A | N/A | N/A |
Where MINIMED GROUP INC Ranks
Frequently Asked Questions
What is MINIMED GROUP INC's annual revenue?
MINIMED GROUP INC (MMED) reported $3.1B in total revenue for fiscal year 2026. This represents a 14.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is MINIMED GROUP INC's revenue growing?
MINIMED GROUP INC (MMED) revenue grew by 14.3% year-over-year, from $2.7B to $3.1B in fiscal year 2026.
Is MINIMED GROUP INC profitable?
No, MINIMED GROUP INC (MMED) reported a net income of -$333.0M in fiscal year 2026, with a net profit margin of -10.7%.
What is MINIMED GROUP INC's EBITDA?
MINIMED GROUP INC (MMED) had EBITDA of -$34.0M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
What is MINIMED GROUP INC's gross margin?
MINIMED GROUP INC (MMED) had a gross margin of 54.2% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.
What is MINIMED GROUP INC's operating margin?
MINIMED GROUP INC (MMED) had an operating margin of -6.1% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.
What is MINIMED GROUP INC's net profit margin?
MINIMED GROUP INC (MMED) had a net profit margin of -10.7% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.
What is MINIMED GROUP INC's return on equity (ROE)?
MINIMED GROUP INC (MMED) has a return on equity of -9.2% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is MINIMED GROUP INC's free cash flow?
MINIMED GROUP INC (MMED) recorded an outflow of $420.0M in free cash flow during fiscal year 2026. This represents a -692.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is MINIMED GROUP INC's operating cash flow?
MINIMED GROUP INC (MMED) recorded an outflow of $197.0M in operating cash flow during fiscal year 2026, representing cash used by core business activities.
What are MINIMED GROUP INC's total assets?
MINIMED GROUP INC (MMED) had $4.6B in total assets as of fiscal year 2026, including both current and long-term assets.
What are MINIMED GROUP INC's capital expenditures?
MINIMED GROUP INC (MMED) invested $223.0M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
How much does MINIMED GROUP INC spend on research and development?
MINIMED GROUP INC (MMED) invested $448.0M in research and development during fiscal year 2026.
What is MINIMED GROUP INC's current ratio?
MINIMED GROUP INC (MMED) had a current ratio of 1.92 as of fiscal year 2026, which is generally considered healthy.
What is MINIMED GROUP INC's debt-to-equity ratio?
MINIMED GROUP INC (MMED) had a debt-to-equity ratio of 0.28 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is MINIMED GROUP INC's return on assets (ROA)?
MINIMED GROUP INC (MMED) had a return on assets of -7.2% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is MINIMED GROUP INC's P/E ratio?
MINIMED GROUP INC (MMED) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2026). The market capitalization is $6.6B as of Sep 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is MINIMED GROUP INC's price-to-sales ratio?
MINIMED GROUP INC (MMED) trades at 2.1x sales, its market capitalization divided by revenue of $3.1B revenue, FY2026. The market capitalization is $6.6B as of Sep 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does MINIMED GROUP INC's liquidity compare with its operating cash outflow?
At the end of fiscal year 2026, MINIMED GROUP INC (MMED) held $298.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $197.0M over that year. Dividing the one by the other, the reported balance equals about 18 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is MINIMED GROUP INC's Altman Z-Score?
MINIMED GROUP INC (MMED) has an Altman Z-Score of 4.53, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is MINIMED GROUP INC's Piotroski F-Score?
MINIMED GROUP INC (MMED) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are MINIMED GROUP INC's earnings high quality?
MINIMED GROUP INC (MMED) reported a net loss of $333.0M while operations used $197.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is MINIMED GROUP INC?
MINIMED GROUP INC (MMED) scores 49 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.